Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial.

BMC Cancer · 2022 · PMC9795638 · PMID 36577958

Europe PMC DOI

hedged sentence

0.0720

closest p · 1.4× alpha

0.0720

boldest claim

The sentences

marginal significanceP = 0.072so close (0.05 < p ≤ 0.1)

TX group included more old patients (> 50: 61.1% vs 42.2%) than TE group, with a marginal significance ( P = 0.072).

also in 5,069 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.